Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis

D. L.M. Van Broekhoven, J. P. Deroose, S. Bonvalot, A. Gronchi, D. J. Grünhagen, A. M.M. Eggermont, C. Verhoef

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)

Abstract

Background: Aggressive fibromatoses (desmoid tumours) may be locally aggressive, but do not metasta-size. Although a conservative approach is advocated for most patients, pain and functional impairment are indications for active treatment. Tumour necrosis factor (TNF) α and melphalan-based isolated limb perfusion (TM-ILP) is a limb-saving treatment modality for soft tissue tumours. This study reports the results of TM-ILP treatment in patients with aggressive fibromatosis.

Methods: Institutional databases of three European centres were searched. All patients who received TM-ILP treatment for aggressive fibromatosis between 1990 and 2012 were included. Before therapy, the patients were discussed at multidisciplinary tumour board meetings.

Results: Twenty-five patients received 28 TM-ILP treatments. The median age of patients was 28 (i.q.r. 19-34) years and median hospital stay was 8 (7-12) days. Median follow-up was 84 (34-114) months. A complete response was achieved after two TM-ILP treatments, and a partial response after 17 treatments in 16 patients. Stable disease was reported after eight treatments in seven patients, including a patient with stable disease after the first treatment and progression after the second TM-ILP. Toxicity was modest after most treatments; Wieberdink grade IV (extensive epidermolysis, and threatening or manifest compartment syndrome) was seen after two TM-ILP treatments. Systemic leakage was reported after one treatment, but did not lead to systemic toxicity. Functional outcome was good; 16 patients had no physical limitations, and six patients had some limitations but did not need medical aids. Amputation was prevented in all but three patients.

Conclusion: TNF-α-based ILP is effective in patients with aggressive fibromatosis.

Original languageEnglish
Pages (from-to)1674-1680
Number of pages7
JournalBritish Journal of Surgery
Volume101
Issue number13
DOIs
Publication statusPublished - 1 Dec 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis'. Together they form a unique fingerprint.

Cite this